Trial Profile
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-MM3
- Sponsors Takeda; Takeda Development Center Americas; Takeda Oncology
- 28 Mar 2024 This trial has been completed in Pprtugal, According to European Clinical Trials Database record.
- 08 Mar 2024 This trial has been completed in Austria, According to European Clinical Trials Database record.
- 07 Nov 2023 This trial has been completed in Czechia (End Date: 08 Sep 2023), according to European Clinical Trials Database record.